Cancer Protein Description

This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.


Protein Name: SYNE1
Gene Name: SYNE1
Protein Full Name: Nesprin-1
Alias: 8B; C6orf98; CPG2; DJ45H2.2; Enaptin; KIAA0796; MYNE1; Myne-1; Myocyte nuclear envelope protein 1; Nesprin-1; Nuclear envelope spectrin repeat protein 1; Spectrin repeat containing, nuclear envelope 1; Synaptic nuclear envelope protein 1; Syne-1; SYNE-1B
Mass (Da): 112393
Number AA: 982
UniProt ID: Q8NF91
Locus ID: 23345
COSMIC ID: SYNE1
Gene location on chromosome: 6q25.1
Cancer protein type: TSP
Effect of cancer mutation on protein: LOSS
Effect of active protein on cancer: iNHIBITS
Number of cancer specimens: 19951
Percent of cancer specimens with mutations: 7.03
General distribution of mutations: Multi-site
Location of most mutations: Broad distribution of mutation sites with many point mutations, two insertions and two deletions, but no complex mutants.
Gene undergoes hypermethylation: Colorectal cancer
Normal role description: SYNE1 is a multi-isomeric modular protein which forms a linking network between organelles and the actin cytoskeleton to maintain the subcellular spatial organization. It is a component of SUN-protein-containing multivariate complexes also called LINC complexes which link the nucleoskeleton and cytoskeleton by providing versatile outer nuclear membrane attachment sites for cytoskeletal filaments. It is involved in the maintenance of nuclear organization and structural integrity, and connects nuclei to the cytoskeleton by interacting with the nuclear envelope and with F-actin in the cytoplasm. It is required for centrosome migration to the apical cell surface during early ciliogenesis. Defects in SYNE1 are the cause of spinocerebellar ataxia autosomal recessive type 8; and of Emery-Dreifuss muscular dystrophy type 4. Promoter hypermethylation of the gene is seen in colorectal cancer.
Commentary on involvement of protein in cancer: 9/468 (2%) CNS tumours; 100% of pharyngeal samples (frameshift deletion, non-sense, mis-sense and silent mutations); and 100% of laryngeal samples (mis-sense, non-sense, silent, and intronic substitutions) were also mutated (Sanger COSMIC)


Provide the gene name, protein name, UniProt ID or Locus ID as a search term. Click on Retrieve Info button to obtain information on the selected cancer protein.